CP-424,174 is a cytokine release inhibitory drugs (CRID) that inhibits the post-translational processing and secretion of IL-1b in response to LPS and ATP in human monocytes. It is quite possible that similarly to CP-456,773 (termed CRID3), CP-424,174 inhibits both NLRP3 and AIM2 inflammasomes by preventing ASC oligomerisation.
Journal of immunology (Baltimore, Md. : 1950), 168(6), 3024-3032 (2002-03-09)
Human monocytes stimulated with LPS produce large quantities of prointerleukin-1beta, but little of this cytokine product is released extracellularly as the mature biologically active species. To demonstrate efficient proteolytic cleavage and export, cytokine-producing cells require a secondary effector stimulus. In
The Inflammasomes are multi-protein complexes that regulate caspase-1 activation and the production of the pro-inflammatory cytokine IL-1β. Previous studies identified a class of diarylsulfonylurea containing compounds called Cytokine Release Inhibitory Drugs (CRIDs) that inhibited the post-translational processing of IL-1β. Further
The Journal of pharmacology and experimental therapeutics, 299(1), 187-197 (2001-09-19)
Lipopolysaccharide (LPS)-activated monocytes and macrophages produce large quantities of pro-interleukin (IL)-1beta but externalize little mature cytokine. Efficient post-translational processing of the procytokine occurs in vitro when these cells encounter a secretion stimulus such as ATP, cytolytic T cells, or hypotonic
Questions
Reviews
★★★★★ No rating value
Active Filters
Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.
